Summary

The global Pharmaceutical Contract Manufacturing & Contract market is projected to grow from US$ 146631 million in 2025 to US$ 242110 million by 2032, at a CAGR of 7.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Pharmaceutical Contract Manufacturing & Contract refers to third-party pharmaceutical development and manufacturing services provided under contractual arrangements to pharmaceutical companies, biotechnology companies and other drug developers. The research object covers activities across the pharmaceutical product lifecycle, including process and formulation development, scale-up and technology transfer, active pharmaceutical ingredient manufacturing, finished dosage form development and production, pharmaceutical packaging, and clinical-stage manufacturing and supply. Service providers combine development expertise, GMP manufacturing infrastructure, analytical and quality-control capabilities, regulatory-compliance systems and commercial-scale production resources to support the transition of drug candidates from development through clinical supply and commercial manufacturing. Within the established research framework, Pharmaceutical Contract Manufacturing & Contract is classified into API CDMO, FDF CDMO, Packaging CDMO and Clinical CDMO, while downstream demand is primarily generated by pharmaceutical companies and biotechnology companies.
Key Findings
Asia Pacific represented approximately 36.5% of 2025 market revenue
API CDMO accounted for about 40.5% of 2025 market revenue
Pharmaceutical companies generated approximately 62.7% of 2025 downstream demand
Top five providers accounted for only 14.15% of 2025 revenue
FDF CDMO share is projected to reach 38.3% by 2032
Market Trends
Pharmaceutical Contract Manufacturing & Contract is evolving from capacity-based outsourced production toward integrated development and manufacturing partnerships covering a broader portion of the drug lifecycle. Pharmaceutical and biotechnology customers increasingly require providers to combine process development, analytical capabilities, technology transfer, clinical manufacturing, commercial production and packaging within coordinated service platforms. At the product level, the market is gradually shifting toward higher-value finished dosage form manufacturing and technically demanding projects involving sterile products, biologics and other complex modalities. Flexible capacity, faster project transfer, scalable manufacturing and consistent quality systems are consequently becoming more important selection criteria. The segment structure illustrates this transition: API CDMO remains the largest category, but its share is expected to decline gradually, while FDF CDMO continues to gain share and is projected to become the largest segment by 2032.
Market Dynamics
Drivers
The principal driver of Pharmaceutical Contract Manufacturing & Contract is the continuing strategic shift by drug developers toward externalized development and manufacturing. Building and maintaining GMP-compliant facilities requires substantial capital, specialized personnel and continuous regulatory investment, making outsourcing economically attractive for companies seeking to preserve capital and increase operational flexibility. At the same time, expanding pharmaceutical pipelines, biologics development and increasingly complex formulations are increasing demand for specialized manufacturing capabilities that are difficult to replicate internally. Small and mid-sized biotechnology companies provide an additional structural demand source because many operate asset-light models and depend on external partners for process scale-up, clinical supply and commercialization. These factors support sustained expansion of the contract manufacturing model across both development-stage and commercial products.
Restraints
The market is constrained by high capital intensity, long qualification cycles and substantial compliance costs. Advanced API plants, sterile filling lines, biologics facilities and specialized manufacturing platforms require significant upfront investment before utilization reaches commercially attractive levels. Capacity additions therefore expose providers to project delays, changes in customer pipelines and potential underutilization. In parallel, pharmaceutical customers maintain strict supplier qualification requirements, making it difficult for new capacity to translate immediately into revenue. Raw-material availability, specialized equipment lead times and shortages of experienced technical and quality personnel can also restrict operational flexibility and raise the cost of maintaining reliable multi-site manufacturing networks.
Opportunities
The strongest opportunities are increasingly concentrated in higher-complexity and higher-value services rather than conventional capacity expansion alone. FDF manufacturing, sterile processing, integrated development-to-commercial services and specialized drug modalities create opportunities for providers capable of combining technical development with scalable GMP production. Biotechnology companies also represent an expanding opportunity as outsourced manufacturing becomes embedded in their operating models. Providers able to support customers from early clinical batches through validation and commercial supply can increase project continuity and customer lifetime value, while geographic capacity diversification provides additional opportunities to serve customers seeking resilient pharmaceutical supply chains and regionally balanced manufacturing strategies.
Challenges
The principal long-term challenge is balancing aggressive capacity investment with uncertain project timing and increasingly demanding quality requirements. Pharmaceutical development programs can be delayed, reprioritized or discontinued, while commercial demand can deviate materially from initial forecasts, creating utilization risk for dedicated assets. Regulatory observations or manufacturing deviations can also disrupt customer programs and materially affect provider credibility. Meanwhile, competition spans large integrated platforms, regional manufacturers and highly specialized providers, requiring companies to differentiate through technology, execution reliability, regulatory performance and customer service rather than capacity alone. Managing complex technology transfers across sites while maintaining consistent quality and delivery performance remains a critical operational challenge.
Industry Chain Analysis
The Pharmaceutical Contract Manufacturing & Contract industry chain begins with upstream suppliers of pharmaceutical starting materials, intermediates, APIs, excipients, single-use systems, packaging materials, laboratory consumables and specialized pharmaceutical manufacturing equipment. These inputs influence production reliability, compliance requirements and manufacturing economics, particularly for sterile, biologic and other technically complex processes. Midstream service providers convert these resources into development and manufacturing capabilities through formulation development, process optimization, analytical development, scale-up, technology transfer, GMP production, filling, packaging and clinical supply management. The value created by a provider therefore depends not simply on manufacturing capacity but on its ability to connect development knowledge, process control, quality systems and reliable scale-up within a unified service model.
Downstream customers are primarily pharmaceutical and biotechnology companies that use contract partners to convert drug candidates or established products into clinical and commercial supply. As projects progress from early development toward commercialization, customer switching costs generally increase because manufacturing processes, analytical methods, regulatory documentation and validated production systems become increasingly interconnected. This creates a value-chain advantage for providers capable of retaining programs across multiple development stages. Profitability consequently varies considerably by service mix, capacity utilization, technical complexity, regulatory track record and degree of customer integration rather than being determined solely by production volume.
Segment Insights
By service type, API CDMO represented approximately 40.5% of Pharmaceutical Contract Manufacturing & Contract revenue in 2025, remaining the largest segment, while FDF CDMO accounted for approximately 34.4%. Packaging CDMO and Clinical CDMO represented approximately 16.3% and 8.9%, respectively. The structure is expected to change gradually as customers increasingly outsource downstream formulation, drug-product manufacturing and integrated commercialization activities.
FDF CDMO is the most notable structural growth segment within the established classification. Its share is projected to rise to approximately 38.3% by 2032, compared with approximately 35.9% for API CDMO, indicating a shift in value creation toward finished dosage forms and more integrated downstream manufacturing. Packaging CDMO is also expected to gain modest share, while Clinical CDMO remains a smaller but strategically important segment connecting development-stage programs with later commercial manufacturing.
Downstream Market Opportunities
Pharmaceutical companies remain the largest downstream customer group, accounting for approximately 62.7% of market demand in 2025, while biotechnology companies represented approximately 34.8%. The opportunity profile differs between these groups. Large pharmaceutical companies increasingly use contract partners to optimize manufacturing networks, supplement internal capacity and access specialized technologies, whereas biotechnology companies often rely more extensively on external partners because they possess limited manufacturing infrastructure. As biologics and specialized therapies represent a larger portion of development pipelines, biotechnology customers are expected to become increasingly important for providers offering development, clinical manufacturing and scalable commercial production within a continuous service relationship.
Regional Insights
Asia Pacific was the largest regional Pharmaceutical Contract Manufacturing & Contract market in 2025, representing approximately 36.5% of global revenue, followed by North America at approximately 30.2% and Europe at approximately 20.6%. Asia Pacific combines established pharmaceutical manufacturing infrastructure, expanding biotechnology activity, competitive production economics and increasing capabilities in technically demanding contract services. Its share is projected to rise to approximately 38.1% by 2032, reinforcing the region's role as a major global outsourcing and manufacturing hub.
North America remains a high-value market characterized by strong pharmaceutical and biotechnology pipelines, substantial demand for advanced manufacturing and close integration between development-stage companies and contract service providers. Europe maintains an important position through established pharmaceutical manufacturing clusters, regulatory expertise and specialized API and finished-dose capabilities. South America and the Middle East & Africa remain smaller in absolute terms but provide incremental opportunities as pharmaceutical manufacturing investment, localization initiatives and regional medicine demand expand. The resulting regional structure favors providers able to combine global manufacturing networks with localized regulatory, supply-chain and customer-management capabilities.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pharmaceutical Contract Manufacturing & Contract market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CMO
FDF CMO
Packaging CMO
Clinical CMO
Segment by Drug Molecules
Small Molecule CMO
Biologics CMO
Cell & Gene Therapy CMO
Peptide & Oligonucleotide CMO
Segment by Doses Form
Oral Solid Dose CMO
Sterile Injectable CMO
Liquid & Semi-solid Dosage Form CMO
Inhalation & Nasal Drug CMO
Other Dosage Form CMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Pharmaceutical Contract Manufacturing & Contract study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Pharmaceutical Contract Manufacturing & Contract: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pharmaceutical Contract Manufacturing & Contract Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 API CMO
1.2.3 FDF CMO
1.2.4 Packaging CMO
1.2.5 Clinical CMO
1.3 Market Segmentation by Drug Molecules
1.3.1 Global Pharmaceutical Contract Manufacturing & Contract Market Size by Drug Molecules, 2021 vs 2025 vs 2032
1.3.2 Small Molecule CMO
1.3.3 Biologics CMO
1.3.4 Cell & Gene Therapy CMO
1.3.5 Peptide & Oligonucleotide CMO
1.4 Market Segmentation by Doses Form
1.4.1 Global Pharmaceutical Contract Manufacturing & Contract Market Size by Doses Form, 2021 vs 2025 vs 2032
1.4.2 Oral Solid Dose CMO
1.4.3 Sterile Injectable CMO
1.4.4 Liquid & Semi-solid Dosage Form CMO
1.4.5 Inhalation & Nasal Drug CMO
1.4.6 Other Dosage Form CMO
1.5 Market Segmentation by Application
1.5.1 Global Pharmaceutical Contract Manufacturing & Contract Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical Company
1.5.3 Biotechnology Company
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Pharmaceutical Contract Manufacturing & Contract Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pharmaceutical Contract Manufacturing & Contract Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Pharmaceutical Contract Manufacturing & Contract Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Pharmaceutical Contract Manufacturing & Contract Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 API CMO: Market Share by Key Players
3.3.2 FDF CMO: Market Share by Key Players
3.3.3 Packaging CMO: Market Share by Key Players
3.3.4 Clinical CMO: Market Share by Key Players
3.4 Global Pharmaceutical Contract Manufacturing & Contract Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Pharmaceutical Contract Manufacturing & Contract Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Pharmaceutical Contract Manufacturing & Contract Market by Drug Molecules
4.2.1 Global Revenue by Drug Molecules (2021-2032)
4.2.2 Global Revenue-Based Market Share by Drug Molecules (2021-2032)
4.3 Global Pharmaceutical Contract Manufacturing & Contract Market by Doses Form
4.3.1 Global Revenue by Doses Form (2021-2032)
4.3.2 Global Revenue-Based Market Share by Doses Form (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Pharmaceutical Contract Manufacturing & Contract Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Pharmaceutical Contract Manufacturing & Contract Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pharmaceutical Contract Manufacturing & Contract Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Pharmaceutical Contract Manufacturing & Contract Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pharmaceutical Contract Manufacturing & Contract Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Pharmaceutical Contract Manufacturing & Contract Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pharmaceutical Contract Manufacturing & Contract Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.1.4 Lonza Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Pharmaceutical Contract Manufacturing & Contract Revenue by Product in 2025
11.1.6 Lonza Pharmaceutical Contract Manufacturing & Contract Revenue by Application in 2025
11.1.7 Lonza Pharmaceutical Contract Manufacturing & Contract Revenue by Geographic Area in 2025
11.1.8 Lonza Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Catalent
11.2.1 Catalent Corporation Information
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.2.4 Catalent Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.2.5 Catalent Pharmaceutical Contract Manufacturing & Contract Revenue by Product in 2025
11.2.6 Catalent Pharmaceutical Contract Manufacturing & Contract Revenue by Application in 2025
11.2.7 Catalent Pharmaceutical Contract Manufacturing & Contract Revenue by Geographic Area in 2025
11.2.8 Catalent Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
11.2.9 Catalent Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.3.4 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.3.5 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract Revenue by Product in 2025
11.3.6 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract Revenue by Application in 2025
11.3.7 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract Revenue by Geographic Area in 2025
11.3.8 Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Corporation Information
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.4.4 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.4.5 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract Revenue by Product in 2025
11.4.6 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract Revenue by Application in 2025
11.4.7 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract Revenue by Geographic Area in 2025
11.4.8 Samsung Biologics Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
11.4.9 Samsung Biologics Recent Developments
11.5 Fareva
11.5.1 Fareva Corporation Information
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.5.4 Fareva Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.5.5 Fareva Pharmaceutical Contract Manufacturing & Contract Revenue by Product in 2025
11.5.6 Fareva Pharmaceutical Contract Manufacturing & Contract Revenue by Application in 2025
11.5.7 Fareva Pharmaceutical Contract Manufacturing & Contract Revenue by Geographic Area in 2025
11.5.8 Fareva Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
11.5.9 Fareva Recent Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Corporation Information
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.6.4 WuXi AppTech Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.6.5 WuXi AppTech Recent Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Corporation Information
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.7.4 WuXi Biologics Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.7.5 WuXi Biologics Recent Developments
11.8 Siegfried
11.8.1 Siegfried Corporation Information
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.8.4 Siegfried Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.8.5 Siegfried Recent Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.10 Asymchem
11.10.1 Asymchem Corporation Information
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.10.4 Asymchem Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Corporation Information
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.11.4 Pfizer CentreOne Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.11.5 Pfizer CentreOne Recent Developments
11.12 Delpharm
11.12.1 Delpharm Corporation Information
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.12.4 Delpharm Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.12.5 Delpharm Recent Developments
11.13 Recipharm
11.13.1 Recipharm Corporation Information
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.13.4 Recipharm Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.13.5 Recipharm Recent Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Corporation Information
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.14.4 AGC Pharma Chemicals Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.14.5 AGC Pharma Chemicals Recent Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.15.4 Boehringer Ingelheim Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.15.5 Boehringer Ingelheim Recent Developments
11.16 Vetter
11.16.1 Vetter Corporation Information
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.16.4 Vetter Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.16.5 Vetter Recent Developments
11.17 Curia
11.17.1 Curia Corporation Information
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.17.4 Curia Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.17.5 Curia Recent Developments
11.18 Aenova
11.18.1 Aenova Corporation Information
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.18.4 Aenova Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.18.5 Aenova Recent Developments
11.19 Porton
11.19.1 Porton Corporation Information
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.19.4 Porton Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.19.5 Porton Recent Developments
11.20 Piramal
11.20.1 Piramal Corporation Information
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.20.4 Piramal Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.20.5 Piramal Recent Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Corporation Information
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.21.4 Strides Pharma Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.21.5 Strides Pharma Recent Developments
11.22 NextPharma
11.22.1 NextPharma Corporation Information
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.22.4 NextPharma Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.22.5 NextPharma Recent Developments
11.23 Famar
11.23.1 Famar Corporation Information
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.23.4 Famar Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.23.5 Famar Recent Developments
11.24 Jubilant
11.24.1 Jubilant Corporation Information
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.24.4 Jubilant Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.24.5 Jubilant Recent Developments
11.25 Alcami
11.25.1 Alcami Corporation Information
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.25.4 Alcami Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.25.5 Alcami Recent Developments
11.26 Euroapi
11.26.1 Euroapi Corporation Information
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.26.4 Euroapi Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.26.5 Euroapi Recent Developments
11.27 Eurofins
11.27.1 Eurofins Corporation Information
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.27.4 Eurofins Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.27.5 Eurofins Recent Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Corporation Information
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.28.4 Avid Bioservices Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.28.5 Avid Bioservices Recent Developments
11.29 BioVectra
11.29.1 BioVectra Corporation Information
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.29.4 BioVectra Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.29.5 BioVectra Recent Developments
11.30 CPL
11.30.1 CPL Corporation Information
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical Contract Manufacturing & Contract Product Features and Attributes
11.30.4 CPL Pharmaceutical Contract Manufacturing & Contract Revenue and Gross Margin (2021-2026)
11.30.5 CPL Recent Developments

12 Pharmaceutical Contract Manufacturing & Contract Value Chain and Ecosystem Analysis
12.1 Pharmaceutical Contract Manufacturing & Contract Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Pharmaceutical Contract Manufacturing & Contract Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Pharmaceutical Contract Manufacturing & Contract Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Drug Molecules, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Doses Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Players (US$ Million), 2021-2026
Table 10. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Pharmaceutical Contract Manufacturing & Contract Revenue, 2025
Table 13. Global Pharmaceutical Contract Manufacturing & Contract Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Pharmaceutical Contract Manufacturing & Contract Companies Headquarters
Table 15. Global Pharmaceutical Contract Manufacturing & Contract Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Type (US$ Million), 2021-2026
Table 19. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Type (US$ Million), 2027-2032
Table 20. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Drug Molecules (US$ Million), 2021-2026
Table 21. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Drug Molecules (US$ Million), 2027-2032
Table 22. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Doses Form (US$ Million), 2021-2026
Table 23. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Doses Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Application (US$ Million), 2021-2026
Table 26. Global Pharmaceutical Contract Manufacturing & Contract Revenue by Application (US$ Million), 2027-2032
Table 27. Pharmaceutical Contract Manufacturing & Contract High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Pharmaceutical Contract Manufacturing & Contract Growth Accelerators and Market Barriers
Table 31. North America Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Pharmaceutical Contract Manufacturing & Contract Growth Accelerators and Market Barriers
Table 33. Europe Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Pharmaceutical Contract Manufacturing & Contract Investment Opportunities and Key Challenges
Table 37. Central and South America Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Corporation Information
Table 41. Lonza Description and Major Businesses
Table 42. Lonza Product Features and Attributes
Table 43. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Revenue Proportion by Product in 2025
Table 45. Lonza Revenue Proportion by Application in 2025
Table 46. Lonza Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
Table 48. Lonza Recent Developments
Table 49. Catalent Corporation Information
Table 50. Catalent Description and Major Businesses
Table 51. Catalent Product Features and Attributes
Table 52. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Catalent Revenue Proportion by Product in 2025
Table 54. Catalent Revenue Proportion by Application in 2025
Table 55. Catalent Revenue Proportion by Geographic Area in 2025
Table 56. Catalent Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
Table 57. Catalent Recent Developments
Table 58. Thermo Fisher Scientific Corporation Information
Table 59. Thermo Fisher Scientific Description and Major Businesses
Table 60. Thermo Fisher Scientific Product Features and Attributes
Table 61. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Thermo Fisher Scientific Revenue Proportion by Product in 2025
Table 63. Thermo Fisher Scientific Revenue Proportion by Application in 2025
Table 64. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2025
Table 65. Thermo Fisher Scientific Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
Table 66. Thermo Fisher Scientific Recent Developments
Table 67. Samsung Biologics Corporation Information
Table 68. Samsung Biologics Description and Major Businesses
Table 69. Samsung Biologics Product Features and Attributes
Table 70. Samsung Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Samsung Biologics Revenue Proportion by Product in 2025
Table 72. Samsung Biologics Revenue Proportion by Application in 2025
Table 73. Samsung Biologics Revenue Proportion by Geographic Area in 2025
Table 74. Samsung Biologics Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
Table 75. Samsung Biologics Recent Developments
Table 76. Fareva Corporation Information
Table 77. Fareva Description and Major Businesses
Table 78. Fareva Product Features and Attributes
Table 79. Fareva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Fareva Revenue Proportion by Product in 2025
Table 81. Fareva Revenue Proportion by Application in 2025
Table 82. Fareva Revenue Proportion by Geographic Area in 2025
Table 83. Fareva Pharmaceutical Contract Manufacturing & Contract SWOT Analysis
Table 84. Fareva Recent Developments
Table 85. WuXi AppTech Corporation Information
Table 86. WuXi AppTech Description and Major Businesses
Table 87. WuXi AppTech Product Features and Attributes
Table 88. WuXi AppTech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. WuXi AppTech Recent Developments
Table 90. WuXi Biologics Corporation Information
Table 91. WuXi Biologics Description and Major Businesses
Table 92. WuXi Biologics Product Features and Attributes
Table 93. WuXi Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. WuXi Biologics Recent Developments
Table 95. Siegfried Corporation Information
Table 96. Siegfried Description and Major Businesses
Table 97. Siegfried Product Features and Attributes
Table 98. Siegfried Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Siegfried Recent Developments
Table 100. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 101. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 102. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 103. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 105. Asymchem Corporation Information
Table 106. Asymchem Description and Major Businesses
Table 107. Asymchem Product Features and Attributes
Table 108. Asymchem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Asymchem Recent Developments
Table 110. Pfizer CentreOne Corporation Information
Table 111. Pfizer CentreOne Description and Major Businesses
Table 112. Pfizer CentreOne Product Features and Attributes
Table 113. Pfizer CentreOne Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Pfizer CentreOne Recent Developments
Table 115. Delpharm Corporation Information
Table 116. Delpharm Description and Major Businesses
Table 117. Delpharm Product Features and Attributes
Table 118. Delpharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Delpharm Recent Developments
Table 120. Recipharm Corporation Information
Table 121. Recipharm Description and Major Businesses
Table 122. Recipharm Product Features and Attributes
Table 123. Recipharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Recipharm Recent Developments
Table 125. AGC Pharma Chemicals Corporation Information
Table 126. AGC Pharma Chemicals Description and Major Businesses
Table 127. AGC Pharma Chemicals Product Features and Attributes
Table 128. AGC Pharma Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. AGC Pharma Chemicals Recent Developments
Table 130. Boehringer Ingelheim Corporation Information
Table 131. Boehringer Ingelheim Description and Major Businesses
Table 132. Boehringer Ingelheim Product Features and Attributes
Table 133. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Boehringer Ingelheim Recent Developments
Table 135. Vetter Corporation Information
Table 136. Vetter Description and Major Businesses
Table 137. Vetter Product Features and Attributes
Table 138. Vetter Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Vetter Recent Developments
Table 140. Curia Corporation Information
Table 141. Curia Description and Major Businesses
Table 142. Curia Product Features and Attributes
Table 143. Curia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Curia Recent Developments
Table 145. Aenova Corporation Information
Table 146. Aenova Description and Major Businesses
Table 147. Aenova Product Features and Attributes
Table 148. Aenova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Aenova Recent Developments
Table 150. Porton Corporation Information
Table 151. Porton Description and Major Businesses
Table 152. Porton Product Features and Attributes
Table 153. Porton Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Porton Recent Developments
Table 155. Piramal Corporation Information
Table 156. Piramal Description and Major Businesses
Table 157. Piramal Product Features and Attributes
Table 158. Piramal Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Piramal Recent Developments
Table 160. Strides Pharma Corporation Information
Table 161. Strides Pharma Description and Major Businesses
Table 162. Strides Pharma Product Features and Attributes
Table 163. Strides Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Strides Pharma Recent Developments
Table 165. NextPharma Corporation Information
Table 166. NextPharma Description and Major Businesses
Table 167. NextPharma Product Features and Attributes
Table 168. NextPharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. NextPharma Recent Developments
Table 170. Famar Corporation Information
Table 171. Famar Description and Major Businesses
Table 172. Famar Product Features and Attributes
Table 173. Famar Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Famar Recent Developments
Table 175. Jubilant Corporation Information
Table 176. Jubilant Description and Major Businesses
Table 177. Jubilant Product Features and Attributes
Table 178. Jubilant Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Jubilant Recent Developments
Table 180. Alcami Corporation Information
Table 181. Alcami Description and Major Businesses
Table 182. Alcami Product Features and Attributes
Table 183. Alcami Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Alcami Recent Developments
Table 185. Euroapi Corporation Information
Table 186. Euroapi Description and Major Businesses
Table 187. Euroapi Product Features and Attributes
Table 188. Euroapi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Euroapi Recent Developments
Table 190. Eurofins Corporation Information
Table 191. Eurofins Description and Major Businesses
Table 192. Eurofins Product Features and Attributes
Table 193. Eurofins Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Eurofins Recent Developments
Table 195. Avid Bioservices Corporation Information
Table 196. Avid Bioservices Description and Major Businesses
Table 197. Avid Bioservices Product Features and Attributes
Table 198. Avid Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Avid Bioservices Recent Developments
Table 200. BioVectra Corporation Information
Table 201. BioVectra Description and Major Businesses
Table 202. BioVectra Product Features and Attributes
Table 203. BioVectra Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. BioVectra Recent Developments
Table 205. CPL Corporation Information
Table 206. CPL Description and Major Businesses
Table 207. CPL Product Features and Attributes
Table 208. CPL Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. CPL Recent Developments
Table 210. Technologies, Platforms and Infrastructure
Table 211. Distributors List
Table 212. Market Trends and Market Evolution
Table 213. Market Drivers and Opportunities
Table 214. Market Challenges, Risks, and Restraints
Table 215. Research Programs/Design for This Report
Table 216. Key Data Information from Secondary Sources
Table 217. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. API CMO Product Picture
Figure 3. FDF CMO Product Picture
Figure 4. Packaging CMO Product Picture
Figure 5. Clinical CMO Product Picture
Figure 6. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Drug Molecules, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Small Molecule CMO Product Picture
Figure 8. Biologics CMO Product Picture
Figure 9. Cell & Gene Therapy CMO Product Picture
Figure 10. Peptide & Oligonucleotide CMO Product Picture
Figure 11. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Doses Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Oral Solid Dose CMO Product Picture
Figure 13. Sterile Injectable CMO Product Picture
Figure 14. Liquid & Semi-solid Dosage Form CMO Product Picture
Figure 15. Inhalation & Nasal Drug CMO Product Picture
Figure 16. Other Dosage Form CMO Product Picture
Figure 17. Global Pharmaceutical Contract Manufacturing & Contract Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 18. Pharmaceutical Company
Figure 19. Biotechnology Company
Figure 20. Other
Figure 21. Pharmaceutical Contract Manufacturing & Contract Report Years Considered
Figure 22. Global Pharmaceutical Contract Manufacturing & Contract Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 24. Global Pharmaceutical Contract Manufacturing & Contract Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. API CMO Revenue-Based Market Share by Player in 2025
Figure 29. FDF CMO Revenue-Based Market Share by Player in 2025
Figure 30. Packaging CMO Revenue-Based Market Share by Player in 2025
Figure 31. Clinical CMO Revenue-Based Market Share by Player in 2025
Figure 32. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Drug Molecules (2021-2032)
Figure 34. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Doses Form (2021-2032)
Figure 35. Global Pharmaceutical Contract Manufacturing & Contract Revenue-Based Market Share by Application (2021-2032)
Figure 36. North America Pharmaceutical Contract Manufacturing & Contract Revenue YoY (US$ Million), 2021-2032
Figure 37. North America Top 5 Players Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) in 2025
Figure 38. North America Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) by Application (2021-2032)
Figure 39. US Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 40. Canada Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 41. Mexico Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 42. Europe Pharmaceutical Contract Manufacturing & Contract Revenue YoY (US$ Million), 2021-2032
Figure 43. Europe Top 5 Players Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) in 2025
Figure 44. Europe Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) by Application (2021-2032)
Figure 45. Germany Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 46. France Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 47. U.K. Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 48. Italy Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 49. Russia Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 50. Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Revenue YoY (US$ Million), 2021-2032
Figure 51. Asia-Pacific Top 8 Players Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) in 2025
Figure 52. Asia-Pacific Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) by Application (2021-2032)
Figure 53. Indonesia Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 54. Japan Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 55. South Korea Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 56. Australia Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 57. India Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 58. Indonesia Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 59. Vietnam Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 60. Malaysia Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 61. Philippines Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 62. Singapore Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 63. Central and South America Pharmaceutical Contract Manufacturing & Contract Revenue YoY (US$ Million), 2021-2032
Figure 64. Central and South America Top 5 Players Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) in 2025
Figure 65. Central and South America Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) by Application (2021-2032)
Figure 66. Brazil Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 67. Argentina Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 68. Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Revenue YoY (US$ Million), 2021-2032
Figure 69. Middle East and Africa Top 5 Players Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) in 2025
Figure 70. Middle East and Africa Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million) by Application (2021-2032)
Figure 71. GCC Countries Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 72. Israel Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 73. Egypt Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 74. South Africa Pharmaceutical Contract Manufacturing & Contract Revenue (US$ Million), 2021-2032
Figure 75. Pharmaceutical Contract Manufacturing & Contract Value Chain Mapping
Figure 76. Channels of Distribution (Direct Vs Distribution)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed